2 news items
Candel Therapeutics to Host Non-Small Cell Lung Cancer (NSCLC) R&D Breakfast Panel During 2024 ASCO Annual Meeting
CADL
20 May 24
cancer is being conducted under a Special Protocol Assessment by the FDA. About Candel Therapeutics
Candel Therapeutics Receives FDA Orphan Drug Designation For CAN-2409 For The Treatment Of Pancreatic Cancer
CADL
11 Apr 24
and improve disease-free survival. Candel's pivotal phase 3 clinical trial in prostate cancer is being conducted under a Special Protocol Assessment by FDA
- Prev
- 1
- Next